1. வினையூக்கி & ராம்ப்-அவேர் தாக்கக் கணக்கீடு

The announcement under evaluation is the Q2FY27 earnings call transcript filed on 2026-11-12. The call reiterates the ₹3,150 Cr primary partnership with Advent International (via Rasmalai Ltd) to scale capacity from ~2,800 to 7,000–8,000 beds over 3–5 years.

• Freshness & Pricing In: This is already priced in. The preferential issue was approved by the Board on 2026-09-17, passed by shareholders on 2026-10-15, reported in Q2 earnings on 2026-11-03, and received CCI clearance earlier on 2026-11-12. The earnings transcript offers zero incremental surprise.
• Dilution Analysis: A primary equity infusion of ₹3,150 Cr into a ₹9,857 Cr market cap company represents ~24.87% post-money equity dilution (~33% expansion in existing share count). Shares outstanding will expand from ~9.3 Cr to ~12.4 Cr shares.
• Ramp Schedule (3-5 Years):
• Year 1: Minimal revenue impact from fresh Advent capital; capex deployment takes 12–18 months. Growth will be driven by operationalizing existing pipelines (Faridabad, Model Town, Shantived Agra), adding ~15% incremental revenue on top of organic ~15-20% growth.
• Steady-State (Year 4-5): Adding ~4,500-5,000 operational beds. At 65% occupancy and ₹36,000 ARPOB, 4,500 additional beds generate ~₹3,800–4,200 Cr in steady-state annual revenue. Consolidated revenues could scale from ₹1,335 Cr TTM to ~₹4,500–5,000 Cr (+240-275% total top-line expansion, or ~180% steady-state net uplift).
• Earnings & EPS: At a mature 15% PAT margin on ₹4,500 Cr revenue, net profit would reach ₹675 Cr. Divided across the expanded ~12.4 Cr diluted share count, steady-state EPS reaches ~₹54.40 vs current TTM EPS of ₹18.80 (+190% PAT, but +110% EPS uplift due to dilution).

2. Industry Capital Intensity & Structural Growth

• Capital Intensity: HIGH. Greenfield tertiary care beds require ₹80L–₹1.2 Cr per bed; brownfield/lease models require ₹40L–₹60L per bed. Gestation to reach EBITDA breakeven averages 18–24 months.
• Industry Execution Difficulty: HIGH. Scaling from 2,800 to 8,000 beds is an enormous managerial hurdle. Key bottlenecks are clinical talent poaching (oncologists, robotic surgeons), regulatory approvals, and brand building outside core Noida/Greater Noida pockets.
• Structural CAGR: Expected Indian private healthcare delivery CAGR is 12–15%, supported by rising insurance penetration, lifestyle diseases, and medical tourism.

3. SEPA Multibagger Quality Checklist

• EPS Acceleration: Q1FY27 EPS was ₹4.88 (+12% YoY), Q2FY27 PAT rose 17% YoY. Decelerating from prior 30%+ growth due to depreciation and initial operating losses from newly added assets.
• Revenue Momentum: Robust. Q2FY27 revenue grew 52% YoY to ₹431 Cr, driven by new unit consolidation and ARPOB expanding 11% to ~₹36,000.
• ROCE Quality: 8.0%. Sub-par due to substantial capital work-in-progress and acquisition gestation. Fails standard quality gate threshold (15%), though typical for hospital chains mid-expansion.
• Balance Sheet & Ownership: D/E of 0.16 is conservative. The ₹3,150 Cr infusion will make Yatharth virtually net cash rich. Promoter holding is stable at 55.8% (will dilute to ~42% post-Advent deal, remaining in control alongside a marquee sponsor).

4. மதிப்பீட்டுச் சூழ்நிலைகள் (36-48 மாத கால எல்லை)

• Base Case (+40% Upside | Price: ₹1,485):
• Yatharth ramps beds to ~5,500 by FY30. FY30 Revenue reaches ~₹3,300 Cr at 24% EBITDA margin and 14% PAT margin (PAT ₹460 Cr).
• Diluted EPS: ₹37.10.
• Exit Multiple: De-rates to 40x P/E as high-growth phase matures.
• Bull Case (+120% Upside | Price: ₹2,330):
• Rapid asset turnaround, successful brownfield M&A deploying all ₹3,150 Cr by FY29. Capacity reaches ~7,500 beds.
• FY30 Revenue reaches ₹4,600 Cr; ARPOB hits ₹42,000; PAT margin expands to 16% (PAT ₹736 Cr).
• Diluted EPS: ₹59.35.
• Exit Multiple: Sustains 39-40x premium multiple.
• Bear Case (-35% Downside | Price: ₹690):
• Extended gestation on greenfield units, execution delays outside NCR, medical talent attrition.
• Consolidated PAT reaches only ₹280 Cr by FY30 due to high depreciation and lower occupancy (55%).
• Diluted EPS: ₹22.60. P/E de-rates to 30x (inline with lower-tier peers).

5. தீர்ப்பின் காரணம்

Yatharth is backed by solid industry tailwinds and top-tier PE capital. However, with trailing P/E at 56.4x, a 25% dilution overhang, and the Advent deal having been public knowledge since September 2026, the near-term risk-reward is balanced. It earns a POSSIBLE rating with a score of 58.

Yatharth Hospital & Trauma Care Services — Q1 FY27 Investor Presentation Analysis

1. Executive Summary & Growth Trajectory

Standing on 2026-08-11, Yatharth Hospital (YATHARTH) has reported stellar Q1 FY27 results with consolidated revenue rising 51% YoY to ₹392.7 Cr (vs Q1 FY26 ₹257.8 Cr). This represents an annualized revenue run-rate of ~₹1,570 Cr, marking a major top-line step-up compared to FY26 consolidated revenue of ₹1,200 Cr.

The key operational takeaway is the rapid turnaround profile of newly acquired units: - Faridabad Unit: Reached EBITDA breakeven in just 9 months. - Agra Unit: Delivered >20% EBITDA margin in its first full operational quarter. - Adjusted EBITDA Margin: 28.1% (consolidated reported 23.3%), proving that underlying earnings power expands as startup ramp losses clear out. - ARPOB & Occupancy: ARPOB increased 7% YoY to ₹34,758 while occupancy rose to 68% (vs 65% YoY).

2. Industry Dynamics & Capital Intensity

• Capital Intensity: High. Adding hospital beds requires ₹0.5 Cr–₹1.0 Cr per bed in capex. However, Yatharth's balance sheet is virtually debt-free (Debt ₹36 Cr vs Net Worth ₹1,619 Cr, D/E 0.02), eliminating financial leverage risk.
• Execution Dynamics: Multi-specialty care (robotics, oncology, organ transplant) drives higher ARPOB and pricing power. Ramping beds takes 2–3 years, but Yatharth is executing faster than industry peers (EBITDA breakeven in 9 months for Faridabad).
• Industry Growth Rate: Healthcare delivery in North India is growing at ~12–15% CAGR; Yatharth is taking substantial market share (+51% YoY top-line growth).

3. Financial Assessment & SEPA Quality Profile

• Revenue Acceleration: Quarterly revenue sequence: ₹257.8 Cr (Q1FY26) -> ₹279.4 Cr -> ₹320.5 Cr -> ₹342.0 Cr -> ₹392.7 Cr (Q1FY27). YoY growth accelerated from ~20-30% in FY26 to 51% in Q1 FY27.
• Margins: Adjusted EBITDA of 28.1% indicates strong unit economics once beds cross ~50% occupancy.
• ROCE Note: Trailing ROCE stands at 8.0% because capital deployed in new units (Faridabad, Agra, Gurugram) is in the early monetization phase. As occupancy matures towards 70%+, ROCE is expected to double towards 16-18%.
• Valuation: Trailing P/E of 48.2x is in line with peer median (48.4x), but forward P/E compresses rapidly to ~32x given the run-rate PAT expansion.

4. மதிப்பீட்டுச் சூழ்நிலைகள் (24-36 மாத கால எல்லை)

• Base Case (+55%): FY28 Revenue reaches ~₹1,850 Cr with PAT margin expanding to 16.5% (PAT ~₹305 Cr). Market cap re-rates to ~₹12,800 Cr at 42x forward P/E -> Target Price ~₹1,365.
• Bull Case (+95%): Accelerated ramp-up of Gurugram unit + higher ARPOB in oncology/robotics pushes FY28 revenue to ₹2,100 Cr and PAT to ₹360 Cr. Valuation multiples expand to 45x -> Target Price ~₹1,720.
• Bear Case (-20%): Doctor attrition or delay in operationalizing Gurugram capacity slows revenue growth to 15% CAGR and margins stay suppressed at 23% EBITDA. Fair value drops to ₹705.

5. தீர்ப்பின் காரணம்

Given the clean balance sheet, zero governance flags, 51% YoY top-line acceleration, and operational proof of rapid unit breakeven, Yatharth qualifies as a STRONG_CANDIDATE for multi-year compounding.

Yatharth Hospital (YATHARTH) - Point-in-Time Research Report

Analysis Date: 2026-08-10 Current Price: ₹898.8 | Market Cap: ₹8,426 Cr

1. Ramp-Aware Catalyst & Financial Math

• Quarterly Acceleration: Q1 FY27 revenue printed at ₹392.7 Cr (+51% YoY vs ₹257.77 Cr in Q1 FY26). The annualized revenue run-rate based on Q1 FY27 is ~₹1,570 Cr, compared to TTM revenue of ₹1,200 Cr.
• Capacity Expansion Realization: Total bed capacity is scaling to 2,800+ beds (including the newly acquired 250-bed Gurugram asset). Operative beds are currently expanding rapidly, with Faridabad breaking even in EBITDA in only 9 months.
• Year-1 Revenue Uplift: FY27 expected revenue reaches ~₹1,570 Cr (+30.8% YoY growth over FY26 TTM).
• Steady-State Revenue Potential (24-36 Months): At full operational capability of 2,800 beds at 68% target occupancy and ARPOB of ₹35,000, steady-state annual revenue potential reaches ~₹2,430 Cr (+102.5% increase over TTM revenue of ₹1,200 Cr).
• PAT & EPS Bridge: At a steady-state net profit margin (NPM) of ~15.0%, net profit reaches ~₹365 Cr (vs ₹171 Cr TTM), yielding an EPS of ~₹39.0 (+105% EPS uplift).

2. தொழில்துறைச் சூழல் & மூலதனத் தீவிரம்

• Capital Intensity: HIGH. Setting up multi-specialty regional hospital chains requires high upfront fixed asset investment.
• Execution Dynamics: Healthcare expansions carry a 2-3 year gestation cycle. However, Yatharth's proven track record of bringing the Faridabad unit to EBITDA breakeven in 9 months demonstrates best-in-class operational ramp efficiency.
• Structural Growth: Indian private healthcare delivery in NCR is compounding at an estimated 13.5% CAGR, supported by growing medical insurance coverage and specialized medical tourism.

3. மல்டிபேக்கர் தர மதிப்பீடு

• Growth Acceleration: Revenue YoY quarterly growth has accelerated sequentially: Q1 FY26 (36%) -> Q4 FY26 (47%) -> Q1 FY27 (51%).
• Margins: Adjusted EBITDA margins reached 28.1% (reported 23.3% due to gestation costs of new units).
• Balance Sheet: Exceptional balance sheet strength with Net Debt virtually zero (D/E: 0.02) and net worth of ₹1,619 Cr.
• Valuation relative to Peers: P/E sits at 49.2x, presenting an attractive discount compared to regional/national hospital peer median of 59.5x.

4. மதிப்பீட்டுச் சூழ்நிலைகள் (24-36 மாத கால எல்லை)

• Base Case (Target: ₹1,585 | +76% Upside):
• Revenue reaches ₹2,200 Cr by FY28.
• Net margin stabilizes at 15.0% -> PAT ₹330 Cr (EPS ₹35.2).

• Exit P/E assigned: 45x (mild de-rating from current 49x due to larger scale).

• Bull Case (Target: ₹2,340 | +160% Upside):

• Rapid ramp in Model Town and Gurugram units; Revenue reaches ₹2,500 Cr.
• Margin expansion driven by higher ARPOB (oncology/robotics) -> PAT ₹400 Cr (EPS ₹42.6).

• Exit P/E assigned: 55x (re-rating towards peer median of 59.5x).

• Bear Case (Target: ₹672 | -25% Downside):

• Slower occupancy ramp; doctor attrition in key departments.
• Revenue reaches ₹1,500 Cr; Net margin compresses to 13.0% -> PAT ₹195 Cr (EPS ₹20.8).
• Exit P/E de-rates to 32x.

5. Final Verdict & Rationale

Verdict: STRONG_CANDIDATE Score: 82/100

Yatharth Hospital demonstrates classic growth acceleration (+51% YoY top-line growth), superb asset-turnaround speeds, high adjusted EBITDA margins (28.1%), and a pristine balance sheet. Trailing ROCE (8.0%) is temporarily depressed due to equity dilution and gestating beds, but structural operational leverage makes this an outstanding compounder candidate over a 24-36 month horizon.

1. ராம்ப்-அவேர் தாக்கக் கணக்கீடு

• Deal Size & Outlay: Yatharth is acquiring an under-construction hospital asset in Gurugram for Rs 100 Cr cash and plans to spend an additional Rs 100 Cr on capex/equipment. Total capital outlay is Rs 200 Cr, which is ~18.4% of TTM Revenue (Rs 1089 Cr).
• Execution Timeline: Since the building is under construction, we assume 1.5 years to complete construction, equip, and commission the facility, followed by 1.5 years to ramp up occupancy. Total time to steady-state is estimated at 3 years (36 months).
• Year 1 Revenue Uplift: 0%. No operational beds will be active in Year 1 as construction and equipping take place.
• Steady-State Revenue Uplift: At 250 beds, assuming a conservative 60% occupancy (150 occupied beds) and a premium Gurugram ARPOB of Rs 28,000 (higher than current average of Rs 25,080 due to premium micro-market), the asset can generate: 150 beds * Rs 28,000 * 365 days = Rs 153.3 Cr of annual revenue. This represents a 14.1% steady-state revenue uplift over TTM revenue.
• Steady-State EPS Uplift: Assuming a mature EBITDA margin of 24% on the new unit, it would generate Rs 36.8 Cr EBITDA. Deducting Rs 10 Cr depreciation (5% on Rs 200 Cr asset base) and Rs 2 Cr interest/opportunity cost of capital leaves Rs 24.8 Cr PBT. At a 25% tax rate, PAT contribution is Rs 18.6 Cr, representing a 11.3% EPS uplift over TTM PAT of Rs 165 Cr.

2. தொழில்துறை மூலதனத் தீவிரம் & எதிர்பார்க்கப்படும் CAGR

• Capital Intensity: HIGH. Hospital expansion requires significant upfront land, building, and medical equipment capex, leading to long payback periods.
• Execution Difficulty: HIGH. Recruiting and retaining top-tier clinical talent in a highly competitive market like Gurugram is challenging and critical for driving ARPOB.
• Industry CAGR: Estimated at 12-14% structurally, driven by rising insurance penetration, medical tourism, and an aging population.

3. மல்டிபேக்கர் தர மதிப்பீடு

• Financials: Revenue growth is accelerating (Dec 2025: +46.2% YoY vs Jun 2025: +21.6% YoY). Operating margins are strong at ~24%. However, trailing ROCE is low at 8.0% because of the large equity base from the recent IPO and cash yet to be deployed.
• Balance Sheet: Excellent. Debt is negligible at Rs 36 Cr (D/E 0.02), meaning the Rs 200 Cr outlay can be comfortably funded without dilutive equity or high leverage.
• Promoter Holding: Stood at 55.8% as of Mar 2026, down from 61.64% in Sep 2025. While still healthy, the promoter selling is a point of caution.

4. Valuation & Scenarios (36-Month Horizon)

• Base Case (50% Upside): Existing assets (Agra, Faridabad, Model Town) ramp up successfully, maintaining 20%+ organic earnings growth. Gurugram asset commissions on time by late Year 2 and starts contributing in Year 3. EPS rises to Rs 28.0; P/E moderates to 40x. Target Price: Rs 1,120.
• Bull Case (90% Upside): Faster commissioning of Gurugram; ARPOB touches Rs 33,000 due to high-end oncology/robotics. EPS reaches Rs 32.5; P/E remains premium at 45x. Target Price: Rs 1,462.
• Bear Case (-15% Downside): Execution delays in Gurugram, high doctor attrition, and intense competition compress margins. EPS grows slowly to Rs 21.0; P/E de-rates to 30x. Target Price: Rs 630.

5. தீர்ப்பின் காரணம்

Yatharth is a high-growth regional hospital player executing a logical expansion into the premium Gurugram market. While the acquisition is highly strategic and backed by a clean balance sheet, the high capital intensity and 2-3 year gestation period of an under-construction asset mean the catalyst will not yield immediate earnings. Consequently, it is classified as a 'POSSIBLE' multibagger rather than a 'STRONG_CANDIDATE' at this stage.